ClinicalTrials.gg
CompletedNCT04090658Updated Feb 25, 2022Results posted

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

A Phase 1 interventional study of RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B and Placebo in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 1 site in Japan. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.

Enrollment
36th of 40
40 · median 642
Started
2019
with 5 others
Phase 1
5 of 40
none open now
Registered
12th of 40
by date

Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 36th largest by enrollment, is one of 6 that started in 2019, is one of 5 in phase 1, and was the 12th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 doses of GSK Biologicals' RSV candidate vaccine adjuvanted with AS01B for the prevention of lower respiratory tract diseases caused by RSV in ethnic Japanese adults 60-80 years of age.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written obtained from the subject prior to performance of any study specific procedure.
  • A male or female between, and including, 60 and 80 years of age at the time of the first vaccination.
  • Subjects with residence status allowing free mixing with general community or in an assisted-living facility that provides minimal assistance, such that the subject is primarily responsible for self-care and activities of daily living, may be enrolled.
  • Japanese ethnic origin (defined as having been born in Japan with four ethnic Japanese grandparents and able to speak Japanese).
  • Subject satisfying screening requirements.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any medical condition that in the judgment of the investigator would make IM injection unsafe.
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness. Patients with chronic stable conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • History of any neurological disorders or seizures.
  • Acute or chronic, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by the investigator based on medical history, physical examination or laboratory screening tests.
  • Hepatomegaly, right upper quadrant abdominal pain or tenderness.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Lymphoproliferative disorder and within 5 years.
  • At screening: Hematology parameters (complete blood cell count [red blood cells, WBC], white blood cells differential count [lymphocytes, neutrophils and eosinophils], count or level) and/or biochemistry parameters (creatinine, blood urea nitrogen or liver enzymes [ or AST]) outside the normal laboratory ranges, unless the laboratory abnormalities are considered not clinically significant by the investigator.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine during the period starting 30 days before the first dose of study vaccine (Day -29 to Day 1), or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 30 days after each study vaccination.
  • Previous vaccination with an RSV vaccine.
  • Known previous administration of a vaccine containing MPL, QS-21 and/or MF59.
  • Planned administration of GSK's Herpes Zoster vaccine marketed as Shingrix or an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine [HZ/su] within 180 days after the second dose of the study vaccine.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For , this will mean prednisone (≥ 20 mg/day, or equivalent). Inhaled and topical steroids are allowed.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccine or planned administration during the study period.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
  • greater than 40 kg/m\^2.
  • Planned move to a location that will prohibit participating in the trial until study end.
  • Bedridden subjects.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    RSV_PreF3_AS01B Group

    Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.

    Biological: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B

  • Placebo comparator
    Placebo Group

    Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.

    Drug: Placebo

Interventions

  • BiologicalRSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B

    Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.

  • DrugPlacebo

    Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose of Vaccination

    Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).

    Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination administered at Day 1

  2. Number of Subjects With Solicited Local AEs After Second Dose of Vaccination

    Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored with a diameter larger than (\>) 20 millimeters (mm).

    Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination administered at Day 61

  3. Number of Subjects With Solicited General AEs After First Dose of Vaccination

    Assessed solicited general AEs solicited were: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.

    Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination administered at Day 1

  4. Number of Subjects With Solicited General AEs After Second Dose of Vaccination

    Assessed solicited general AEs solicited are: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms including (nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.

    Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination administered at Day 61

  5. Number of Subjects With Unsolicited AEs After Any Vaccination

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE.

    Time frame: During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination (across doses)

  6. Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose When Compared to Day 1

    Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.

    Time frame: At 7 days after the first vaccine dose (i.e. at Day 8 versus Day 1)

  7. Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose When Compared to Day 61

    Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.

    Time frame: At 7 days after the second vaccine dose (i.e at Day 68 versus Day 61)

  8. Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination

    A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

    Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first vaccination

  9. Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination

    A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

    Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second vaccination

  10. Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

    Time frame: From Day 1 up to 30 days after the second vaccination (Day 91)

  11. Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology

    Time frame: From Day 1 up to 30 days after the second vaccination (Day 91)

Secondary outcomes

  1. Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV- Serotype A

    Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60). The cut-off of the assay is 18 ED60.

    Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)

  2. Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations

    The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples are based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL). The assay cut-off is 25 ELU/mL.

    Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)

  3. Number of Subjects With Any SAEs, up the End of Follow-up Study Period (Month 14)

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

    Time frame: From Day 1 up to the end of follow-up period (Month 14)

  4. Number of Subjects Reporting pIMDs up to the End of Follow-up Study Period (Month 14)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From Day 1 up to the end of follow-up period (Month 14)

  5. Number of Subjects With Respiratory Tract Infection (RTI) Episodes Reported During RTI Surveillance

    The number of RTI cases is provided by group. Reported categories are "RSV+ RTI" (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab collected at assessment visit) and "RSV- RTI" (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab collected at assessment visit).

    Time frame: During the RSV seasons from Day 1 to Month 14

07

Results

Posted Feb 25, 2022

Participant flow

Participant flow — Overall Study
MilestoneRSV_PreF3_AS01B GroupPlacebo Group
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryNumber of Subjects With Solicited Local Adverse Events (AEs) After First Dose of Vaccination

Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).

Time frame:
During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination administered at Day 1
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose of Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Erythema10
Pain171
Swelling20
PrimaryNumber of Subjects With Solicited Local AEs After Second Dose of Vaccination

Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored with a diameter larger than (\>) 20 millimeters (mm).

Time frame:
During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination administered at Day 61
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local AEs After Second Dose of Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Erythema00
Pain174
Swelling00
PrimaryNumber of Subjects With Solicited General AEs After First Dose of Vaccination

Assessed solicited general AEs solicited were: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.

Time frame:
During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination administered at Day 1
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General AEs After First Dose of Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Arthralgia10
Fatigue92
Fever00
Gastrointestinal symptoms11
Headache22
Myalgia60
Shivering10
PrimaryNumber of Subjects With Solicited General AEs After Second Dose of Vaccination

Assessed solicited general AEs solicited are: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms including (nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.

Time frame:
During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination administered at Day 61
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General AEs After Second Dose of Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Arthralgia50
Fatigue91
Fever40
Gastrointestinal symptoms01
Headache51
Myalgia51
Shivering40
PrimaryNumber of Subjects With Unsolicited AEs After Any Vaccination

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE.

Time frame:
During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination (across doses)
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited AEs After Any Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Number of Subjects With Unsolicited AEs After Any Vaccination76
PrimaryNumber of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose When Compared to Day 1

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.

Time frame:
At 7 days after the first vaccine dose (i.e. at Day 8 versus Day 1)
Reported as:
Count of participants · Participants
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose When Compared to Day 1
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
ALT-Above-Above10
ALT-Within-Within1920
AST-Within-Above01
AST-Within-Within2019
Basophils-Within-Within2020
Creatinine-Within-Below10
Creatinine-Within-Within1920
Eosinophils-Below-Below31
Eosinophils-Below-Within21
Eosinophils-Within-Below21
Eosinophils-Within-Within1317
Erythrocytes-Below-Below01
Erythrocytes-Within-Below22
Erythrocytes-Within-Within1817
Hemoglobin-Below-Below01
Hemoglobin-Within-Below01
Hemoglobin-Within-Within2018
Lymphocytes-Within-Within2020
Monocytes-Below-Below20
Monocytes-Below-Within11
Monocytes-Within-Below10
Monocytes-Within-Within1619
Neutrophils-Below-Below10
Neutrophils-Within-Within1920
Platelets-Within-Within2020
Urea Nitrogen-Above-Within10
Urea Nitrogen-Within-Within1920
Uric Acid-Above-Above10
Uric Acid-Above-Within20
Uric Acid-Within-Above11
Uric Acid-Within-Below10
Uric Acid-Within-Within1519
White Blood Cells-Below-Below10
White Blood Cells-Below-Within02
White Blood Cells-Within-Below10
White Blood Cells-Within-Within1818
PrimaryNumber of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose When Compared to Day 61

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.

Time frame:
At 7 days after the second vaccine dose (i.e at Day 68 versus Day 61)
Reported as:
Count of participants · Participants
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose When Compared to Day 61
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
ALT-Within-Within2020
AST-Within-Above01
AST-Within-Within2019
Basophils-Within-Within2020
Creatinine-Below-Below01
Creatinine-Within-Above01
Creatinine-Within-Below10
Creatinine-Within-Within1918
Eosinophils-Below-Within10
Eosinophils-Within-Above10
Eosinophils-Within-Within1820
Erythrocytes-Below-Below03
Erythrocytes-Below-Within10
Erythrocytes-Within-Below11
Erythrocytes-Within-Within1816
Hemoglobin-Below-Within10
Hemoglobin-Within-Below02
Hemoglobin-Within-Within1918
Lymphocytes-Within-Within2020
Monocytes-Below-Below20
Monocytes-Within-Below20
Monocytes-Within-Within1620
Neutrophils-Below-Below11
Neutrophils-Within-Below01
Neutrophils-Within-Within1918
Platelets-Within-Within2020
Urea Nitrogen-Within-Within2020
Uric Acid-Above-Above01
Uric Acid-Below-Below10
Uric Acid-Within-Above11
Uric Acid-Within-Below10
Uric Acid-Within-Within1718
White Blood Cells-Below-Below10
White Blood Cells-Below-Within21
White Blood Cells-Within-Below01
White Blood Cells-Within-Within1718
PrimaryNumber of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination

A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

Time frame:
During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Any adverse event00
General adverse event00
Local adverse event00
PrimaryNumber of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination

A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

Time frame:
During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Any adverse event20
General adverse event10
Local adverse event10
PrimaryNumber of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

Time frame:
From Day 1 up to 30 days after the second vaccination (Day 91)
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination01
PrimaryNumber of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology

Time frame:
From Day 1 up to 30 days after the second vaccination (Day 91)
Reported as:
Count of participants · Participants
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination00
SecondaryHumoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV- Serotype A

Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60). The cut-off of the assay is 18 ED60.

Time frame:
At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Reported as:
Geometric mean · Titers
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV- Serotype A
TitersRSV_PreF3_AS01B GroupPlacebo Group
Day 1727.3 (445.6 to 1187.3)656 (464.7 to 926.2)
Day 315315 (3452.8 to 8181.5)582.3 (372.1 to 911.2)
Day 614382.8 (2828.1 to 6792.1)646.1 (442.6 to 943.1)
Day 914605.2 (3031.2 to 6996.4)529.9 (352.4 to 796.9)
SecondaryHumoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations

The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples are based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL). The assay cut-off is 25 ELU/mL.

Time frame:
At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Reported as:
Geometric mean · ELU/mL
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations
ELU/mLRSV_PreF3_AS01B GroupPlacebo Group
Day 16676.7 (4490 to 9928.2)7090.2 (5123.8 to 9811.4)
Day 3185282.4 (66071.9 to 110078.4)7242.6 (5534.1 to 9478.6)
Day 6154076.9 (40417.7 to 72352.2)5625.9 (4322.5 to 7322.3)
Day 9161110.7 (45959 to 81257.6)5515.7 (4240.2 to 7174.8)
SecondaryNumber of Subjects With Any SAEs, up the End of Follow-up Study Period (Month 14)

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

Time frame:
From Day 1 up to the end of follow-up period (Month 14)
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs, up the End of Follow-up Study Period (Month 14)
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Number of Subjects With Any SAEs, up the End of Follow-up Study Period (Month 14)01
SecondaryNumber of Subjects Reporting pIMDs up to the End of Follow-up Study Period (Month 14)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From Day 1 up to the end of follow-up period (Month 14)
Reported as:
Count of participants · Participants
Number of Subjects Reporting pIMDs up to the End of Follow-up Study Period (Month 14)
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
Number of Subjects Reporting pIMDs up to the End of Follow-up Study Period (Month 14)00
SecondaryNumber of Subjects With Respiratory Tract Infection (RTI) Episodes Reported During RTI Surveillance

The number of RTI cases is provided by group. Reported categories are "RSV+ RTI" (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab collected at assessment visit) and "RSV- RTI" (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab collected at assessment visit).

Time frame:
During the RSV seasons from Day 1 to Month 14
Reported as:
Count of participants · Participants
Number of Subjects With Respiratory Tract Infection (RTI) Episodes Reported During RTI Surveillance
ParticipantsRSV_PreF3_AS01B GroupPlacebo Group
RSV + RTI00
RSV - RTI11

Adverse events

Collected over Solicited AEs were collected during the 7-day follow-up period after each vaccination. Unsolicited AEs were collected during the 30-day follow-up period after any vaccination. SAEs were collected during the whole study period, from Day 1 till Month 14.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSV_PreF3_AS01B Group0/20 (0%)0/20 (0%)19/20 (95%)
Placebo Group0/20 (0%)1/20 (5%)10/20 (50%)
Most frequent serious events
Most frequent serious events
EventRSV_PreF3_AS01B GroupPlacebo Group
Radius fractureInjury, poisoning and procedural complications0/201/20
Ulna fractureInjury, poisoning and procedural complications0/201/20
Most frequent other events
Showing 10 of 21
Most frequent other events
EventRSV_PreF3_AS01B GroupPlacebo Group
Injection site painGeneral disorders18/204/20
FatigueGeneral disorders13/202/20
MyalgiaMusculoskeletal and connective tissue disorders9/201/20
ArthralgiaMusculoskeletal and connective tissue disorders7/200/20
HeadacheNervous system disorders7/203/20
ChillsGeneral disorders6/200/20
PyrexiaGeneral disorders5/200/20
Injection site swellingGeneral disorders2/200/20
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/201/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/202/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RSV_PreF3_AS01B GroupPlacebo GroupTotal
Mean65.2 ± 5.067.2 ± 4.266.2 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)RSV_PreF3_AS01B GroupPlacebo GroupTotal
Female101020
Male101020
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV_PreF3_AS01B GroupPlacebo GroupTotal
Asian202040
08

Study locations

1 site
  • GSK Investigational Site
    Fukuoka, 812-0025, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jan 2020, 3 months.

Results were first posted in Feb 2022, 2 years 1 month after primary completion.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2019
First posted
Sep 16, 2019
StartActual
Sep 25, 2019
Primary completionActual
Jan 10, 2020
CompletionActual
Dec 11, 2020
Results first posted
Feb 25, 2022
Last update
Feb 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04090658
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Sep 25, 2019
Primary completion
Jan 10, 2020
Completion
Dec 11, 2020
Results posted
Feb 25, 2022
Last update
Feb 25, 2022

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion